La cadena de opciones muestra datos clave de las opciones de acciones de Cocrystal Pharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Cocrystal Pharma..

Cocrystal Pharma (NASDAQ:COCP) Bolsa, Cadena de Opciones

Cocrystal Pharma

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

Cocrystal Pharma Inc

21 analysts have shared their evaluations of Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">13</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">11</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $85.0, with a high estimate of $93.00 and a low estimate of $79.00. This upward trend is apparent, with the current average reflecting a 5.88% increase from the previous average price target of $80.28.
<img src="https://www.benzinga.com/files/images/story/2024/1732557667_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Nasdaq among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$80.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Kevin Heal</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$80.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Patrick O'Shaughnessy</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$82.00</td>
<td>-</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$84.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Alex Kramm</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$79.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Richard Repetto</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$88.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$83.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$88.00</td>
<td>-</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Hold</td>
<td>$83.00</td>
<td>-</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$53.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nasdaq. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Nasdaq compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Nasdaq's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Nasdaq's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NDAQ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Nasdaq analyst ratings.</a>
<h2>Unveiling the Story Behind Nasdaq</h2>
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
<h3>Nasdaq's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3 months period, Nasdaq showcased positive performance, achieving a revenue growth rate of 31.08% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Nasdaq's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 16.09%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Nasdaq's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.79%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Nasdaq's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.01%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Nasdaq's debt-to-equity ratio stands notably higher than the industry average, reaching 0.93. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

NDAQ

Analyst Ratings For Nasdaq

4 analysts have shared their evaluations of Helen Of Troy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HELE#NASDAQ">HELE</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Helen Of Troy, revealing an average target of $81.25, a high estimate of $92.00, and a low estimate of $71.00. Surpassing the previous average price target of $76.50, the current average has increased by 6.21%.
<img src="https://www.benzinga.com/files/images/story/2024/1732557654_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Helen Of Troy. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$71.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$92.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Helen Of Troy. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Helen Of Troy compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Helen Of Troy's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Helen Of Troy's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HELE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Helen Of Troy analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Helen Of Troy Better</h2>
Helen Of Troy Ltd is a consumer products company offering creative products and solutions for its customers through a diversified portfolio of brands. It has two operating segments: Home &amp; Outdoor segment provides a broad range of consumer products for home activities such as food preparation, cooking, cleaning, and organization; as well as products for outdoor and on-the-go activities such as hydration, food storage, backpacks, and travel gear, and The Beauty &amp; Wellness segment provides beauty and wellness products including mass and prestige market beauty appliances, prestige market liquid-based hair and personal care products, and wellness devices including thermometers, water and air filtration systems, humidifiers, and fans.
<h3>Helen Of Troy: Financial Performance Dissected</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Helen Of Troy faced challenges, resulting in a decline of approximately -3.53% in revenue growth as of 31 August, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Helen Of Troy's net margin excels beyond industry benchmarks, reaching 3.59%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Helen Of Troy's ROE stands out, surpassing industry averages. With an impressive ROE of 1.09%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Helen Of Troy's ROA excels beyond industry benchmarks, reaching 0.6%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.48.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HELE

The Latest Analyst Ratings For Helen Of Troy

Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) revealed 13 unusual trades.
Delving into the details, we found 38% of traders were bullish, while 53% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $257,880, and 10 were calls, valued at $538,961.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $160.0 to $192.5 for AbbVie during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for AbbVie's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across AbbVie's significant trades, within a strike price range of $160.0 to $192.5, over the past month.
<h3>AbbVie Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732557634_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.55</td>
<td>$6.3</td>
<td>$6.3</td>
<td>$175.00</td>
<td>$189.0K</td>
<td>689</td>
<td align="right">319</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$14.95</td>
<td>$14.2</td>
<td>$14.2</td>
<td>$165.00</td>
<td>$142.0K</td>
<td>4.0K</td>
<td align="right">107</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$26.75</td>
<td>$26.4</td>
<td>$26.4</td>
<td>$165.00</td>
<td>$124.0K</td>
<td>490</td>
<td align="right">47</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$1.92</td>
<td>$1.78</td>
<td>$1.8</td>
<td>$185.00</td>
<td>$54.0K</td>
<td>3.6K</td>
<td align="right">695</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$3.8</td>
<td>$3.7</td>
<td>$3.7</td>
<td>$180.00</td>
<td>$36.6K</td>
<td>4.7K</td>
<td align="right">328</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>AbbVie's Current Market Status</h3>
<ul>
<li>With a trading volume of 3,563,685, the price of ABBV is up by 0.2%, reaching $177.31.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 67 days from now.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

ABBV

Market Whales and Their Recent Bets on ABBV Options

Investors with a lot of money to spend have taken a bullish stance on AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ASTS, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 15 options trades for AST SpaceMobile.
This isn't normal.
The overall sentiment of these big-money traders is split between 53% bullish and 40%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $66,690, and 14, calls, for a total amount of $914,577.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $12.5 to $35.0 for AST SpaceMobile over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for AST SpaceMobile's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across AST SpaceMobile's significant trades, within a strike price range of $12.5 to $35.0, over the past month.
<h3>AST SpaceMobile Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732557628_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$16.9</td>
<td>$16.5</td>
<td>$16.5</td>
<td>$12.50</td>
<td>$160.0K</td>
<td>16.9K</td>
<td align="right">261</td>
</tr>
<tr>
<td>ASTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$15.3</td>
<td>$15.3</td>
<td>$15.3</td>
<td>$12.50</td>
<td>$116.2K</td>
<td>16.9K</td>
<td align="right">158</td>
</tr>
<tr>
<td>ASTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$15.5</td>
<td>$15.4</td>
<td>$15.4</td>
<td>$12.50</td>
<td>$115.5K</td>
<td>16.9K</td>
<td align="right">79</td>
</tr>
<tr>
<td>ASTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$4.1</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$22.00</td>
<td>$98.8K</td>
<td>4</td>
<td align="right">247</td>
</tr>
<tr>
<td>ASTS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.9</td>
<td>$2.85</td>
<td>$2.85</td>
<td>$25.00</td>
<td>$66.6K</td>
<td>2.5K</td>
<td align="right">243</td>
</tr>
</tbody>
</table>

<h3>About AST SpaceMobile</h3>
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices, and off-the-shelf mobile phones based on extensive IP and patent portfolio. It has focused on eliminating the connectivity gaps faced by mobile subscribers and finally bringing broadband to the billions who remain unconnected. The Company's spaceMobile Service is being designed to provide cost-effective, high-speed Cellular Broadband services to end-users who are out of terrestrial cellular coverage using existing mobile devices.
Having examined the options trading patterns of AST SpaceMobile, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is AST SpaceMobile Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 6,772,881, the ASTS's price is up by 2.03%, now at $24.59. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 126 days.</li>
</ul>
<h3>Expert Opinions on AST SpaceMobile</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $37.85.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Scotiabank keeps a Sector Outperform rating on AST SpaceMobile with a target price of $44. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for AST SpaceMobile, targeting a price of $31. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AST SpaceMobile options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

ASTS

AST SpaceMobile Unusual Options Activity

20 analysts have shared their evaluations of Tractor Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Tractor Supply and provided 12-month price targets. The average target is $300.45, accompanied by a high estimate of $335.00 and a low estimate of $250.00. Witnessing a positive shift, the current average has risen by 4.94% from the previous average price target of $286.32.
<img src="https://www.benzinga.com/files/images/story/2024/1732557629_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Tractor Supply. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$320.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>John Lawrence</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$310.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$272.00</td>
</tr>
<tr>
<td>Matthew McClintock</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$290.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Seth Sigman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>David Bellinger</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$270.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$317.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$335.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>John Lawrence</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$280.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$335.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$290.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$293.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$332.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$325.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Oliver Wintermantel</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>In-Line</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>John Lawrence</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$280.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Karen Short</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Buy</td>
<td>$315.00</td>
<td>-</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Hold</td>
<td>$260.00</td>
<td>$250.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tractor Supply. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Tractor Supply compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Tractor Supply's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TSCO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tractor Supply analyst ratings.</a>
<h2>About Tractor Supply</h2>
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,270 of its namesake banners in 49 states, including 81 Orscheln Farm and Home stores (rebranded as Tractor Supply), along with 205 Petsense by Tractor Supply stores. Stores are generally concentrated in rural communities, as opposed to urban and suburban areas. In fiscal 2023, revenue consisted primarily of livestock, equine &amp; agriculture (27%), companion animal (25%), and seasonal &amp; recreation (22%).
<h3>Tractor Supply: Delving into Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Tractor Supply's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 1.65%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Tractor Supply's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 6.96%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 10.51%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.47%, the company showcases effective utilization of assets.
Debt Management: Tractor Supply's debt-to-equity ratio stands notably higher than the industry average, reaching 2.33. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TSCO

20 Analysts Assess Tractor Supply: What You Need To Know

Whales with a lot of money to spend have taken a noticeably bearish stance on Bank of America.
Looking at options history for Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) we detected 34 trades.
If we consider the specifics of each trade, it is accurate to state that 38% of the investors opened trades with bullish expectations and 61% with bearish.
From the overall spotted trades, 11 are puts, for a total amount of $991,182 and 23, calls, for a total amount of $1,983,979.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $39.0 and $55.0 for Bank of America, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Bank of America's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Bank of America's substantial trades, within a strike price spectrum from $39.0 to $55.0 over the preceding 30 days.
<h3>Bank of America 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732557622_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$1.89</td>
<td>$1.85</td>
<td>$1.89</td>
<td>$40.00</td>
<td>$472.7K</td>
<td>27.2K</td>
<td>497</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$1.25</td>
<td>$1.22</td>
<td>$1.24</td>
<td>$47.00</td>
<td>$368.0K</td>
<td>30.8K</td>
<td>5.2K</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$1.24</td>
<td>$1.21</td>
<td>$1.23</td>
<td>$47.00</td>
<td>$256.7K</td>
<td>30.8K</td>
<td>11.7K</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$1.23</td>
<td>$1.22</td>
<td>$1.22</td>
<td>$47.00</td>
<td>$155.4K</td>
<td>30.8K</td>
<td>4.7K</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$0.58</td>
<td>$0.56</td>
<td>$0.58</td>
<td>$48.50</td>
<td>$120.2K</td>
<td>1.9K</td>
<td>10.6K</td>
</tr>
</tbody>
</table>

<h3>About Bank of America</h3>
Bank of America is one of the largest financial institutions in the United States, with more than $3.0 trillion in assets. It is organized into four major segments: consumer banking, global wealth and investment management, global banking, and global markets. Bank of America's consumer-facing lines of business include its network of branches and deposit-gathering operations, retail lending products, credit and debit cards, and small-business services. The company's Merrill Lynch operations provide brokerage and wealth-management services, as does its private bank. Wholesale lines of business include investment banking, corporate and commercial real estate lending, and capital markets operations. Bank of America has operations in several countries but is primarily US-focused.
Following our analysis of the options activities associated with Bank of America, we pivot to a closer look at the company's own performance.
<h3>Where Is Bank of America Standing Right Now?</h3>
<ul>
<li>With a volume of 13,458,434, the price of BAC is up 0.87% at $47.41. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 52 days.</li>
</ul>
<h3>What Analysts Are Saying About Bank of America</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $55.333333333333336.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Bank of America, maintaining a target price of $56. 
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Bank of America, maintaining a target price of $56. 
&#x2A; Showing optimism, an analyst from Citigroup upgrades its rating to Buy with a revised price target of $54. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Bank of America, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Bank of America Options Trading: A Deep Dive into Market Sentiment

During the last three months, 6 analysts shared their evaluations of Golden Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEN#NASDAQ">GDEN</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $37.33, a high estimate of $40.00, and a low estimate of $35.00. A decline of 3.86% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1732557619_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Golden Entertainment's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jordan Bender</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$36.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Chad Beynon</td>
<td>Macquarie</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Jordan Bender</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$35.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Chad Beynon</td>
<td>Macquarie</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$39.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>David Bain</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Golden Entertainment. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Golden Entertainment compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Golden Entertainment's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Golden Entertainment's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GDEN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Golden Entertainment analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Golden Entertainment: A Closer Look</h2>
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.
<h3>Financial Milestones: Golden Entertainment's Journey</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Challenges: Golden Entertainment's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -37.44%. This indicates a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 3.2%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.98%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.45%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.95, Golden Entertainment adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GDEN

What Analysts Are Saying About Golden Entertainment Stock

BofA Securities downgraded Editas Medicine Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>), citing few value-driving catalysts <a target="_blank" href="https://www.benzinga.com/quote/EDIT/analyst-ratings" rel="noreferrer noopener">in the near term</a>.
In its third-quarter earnings release, Editas Medicine said it engaged an investment bank to lead the process of partnering or out-licensing reni-cel (renizgamglogene autogedtemcel, previously EDIT-301).
The company is developing reni-cel for sickle cell disease and transfusion-<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41710488/editas-medicine-announces-third-quarter-2024-results-and-business-updates" rel="noreferrer noopener">dependent Beta Thalassemia</a>.
The company is on track to share additional clinical and patient-reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology Annual Meeting in December.
The company has completed enrollment of the adult cohort of the EdiTHAL trial for thalassemia and continues patient dosing.
The analyst notes that Editas announced a shift in focus toward in vivo development, specifically working on lipid nanoparticle (LNP) formulations for treating sickle cell disease (SCD) and thalassemia.
While preclinical data shows some progress—29% editing in hematopoietic stem and progenitor cells (HSPCs) and around 20% of red blood cells expressing fetal hemoglobin (HbF)—more evidence is needed to prove functional benefits and advance to clinical trials.
Meanwhile, competitors like Beam Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) and CRISPR Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) are investing heavily in their in vivo programs for SCD and thalassemia, with better-prepared manufacturing and development for clinical trials.
Given the deprioritization of reni-cel and the increasingly competitive environment for ex vivo therapies, BofA has reduced estimates and probabilities of success in SCD and beta-thal to 10% (from 60% prior).
The analyst downgraded from Buy to Underperform, with a price target of $1, down from $13.
This intensifying competition, limited short-term clinical milestones, and declining interest in gene editing pose challenges for Editas and could pressure its stock in the near term.
Price Action: EDIT stock is down 0.41% at $2.43 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/24/11/42168509/amd-teams-up-with-taiwan-semi-to-take-on-samsung-in-smartphone-market" target="_blank" rel="noreferrer noopener">AMD Teams Up With Taiwan Semi To Take On Samsung In Smartphone Market</a></li>
</ul>
Photo by Ground Picture on Shutterstock.

Analyst Color

Biotech

Equities

News

Downgrades

Health Care

Price Target

Trading Ideas

General

BEAM

CRSP

EDIT

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts

Evercore ISI Group analyst Peter Levine maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Outperform and raises the price target from $325 to $400.

CRWD

Evercore ISI Group Maintains Outperform on CrowdStrike Holdings, Raises Price Target to $400

Roth MKM analyst Scott Searle maintains Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) with a Buy and raises the price target from $50 to $60.

SMTC

Roth MKM Maintains Buy on Semtech, Raises Price Target to $60

High-rolling investors have positioned themselves bullish on Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in FI often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 14 options trades for Fiserv. This is not a typical pattern.
The sentiment among these major traders is split, with 64% bullish and 28% bearish. Among all the options we identified, there was one put, amounting to $31,140, and 13 calls, totaling $1,846,413.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $100.0 to $225.0 for Fiserv over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Fiserv's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Fiserv's whale activity within a strike price range from $100.0 to $225.0 in the last 30 days. 
<h3>Fiserv Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732556731_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.4</td>
<td>$28.8</td>
<td>$30.0</td>
<td>$220.00</td>
<td>$450.0K</td>
<td align="right">388</td>
<td align="right">511</td>
</tr>
<tr>
<td>FI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.0</td>
<td>$28.9</td>
<td>$30.0</td>
<td>$220.00</td>
<td>$360.0K</td>
<td align="right">388</td>
<td align="right">309</td>
</tr>
<tr>
<td>FI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$24.3</td>
<td>$23.0</td>
<td>$24.2</td>
<td>$220.00</td>
<td>$207.5K</td>
<td align="right">60</td>
<td align="right">186</td>
</tr>
<tr>
<td>FI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$37.1</td>
<td>$35.6</td>
<td>$37.1</td>
<td>$210.00</td>
<td>$185.5K</td>
<td align="right">46</td>
<td align="right">50</td>
</tr>
<tr>
<td>FI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.7</td>
<td>$29.4</td>
<td>$30.4</td>
<td>$220.00</td>
<td>$152.0K</td>
<td align="right">388</td>
<td align="right">188</td>
</tr>
</tbody>
</table>

<h3>About Fiserv</h3>
Fiserv is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing, for us banks and credit unions, with a focus on small and midsize banks. Through the merger with First Data in 2019, Fiserv also provides payment processing services for merchants. About 10% of the company's revenue is generated internationally.
Having examined the options trading patterns of Fiserv, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Fiserv's Current Market Status</h3>
<ul>
<li>With a trading volume of 993,428, the price of FI is down by -0.49%, reaching $220.47.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 71 days from now.</li>
</ul>
<h3>Expert Opinions on Fiserv</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $251.33333333333334.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Compass Point downgraded its rating to Buy, setting a price target of $278. 
&#x2A; Maintaining their stance, an analyst from Tigress Financial continues to hold a Buy rating for Fiserv, targeting a price of $244. 
&#x2A; An analyst from BMO Capital persists with their Outperform rating on Fiserv, maintaining a target price of $232. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Fiserv, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Fiserv's Options Frenzy: What You Need to Know

Whales with a lot of money to spend have taken a noticeably bullish stance on BP.
Looking at options history for BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 44% of the investors opened trades with bullish expectations and 44% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $166,758 and 5, calls, for a total amount of $1,017,479.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $28.0 to $33.0 for BP over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of BP stands at 6534.14, with a total volume reaching 25,260.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in BP, situated within the strike price corridor from $28.0 to $33.0, throughout the last 30 days.
<h3>BP Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732556726_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$0.82</td>
<td>$0.8</td>
<td>$0.81</td>
<td>$30.00</td>
<td>$724.6K</td>
<td>14.9K</td>
<td>10.0K</td>
</tr>
<tr>
<td>BP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.82</td>
<td>$0.81</td>
<td>$0.81</td>
<td>$30.00</td>
<td>$111.6K</td>
<td>14.9K</td>
<td>12.1K</td>
</tr>
<tr>
<td>BP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.84</td>
<td>$0.81</td>
<td>$0.81</td>
<td>$30.00</td>
<td>$84.4K</td>
<td>14.9K</td>
<td>1.1K</td>
</tr>
<tr>
<td>BP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$0.91</td>
<td>$0.9</td>
<td>$0.91</td>
<td>$28.00</td>
<td>$62.0K</td>
<td>132</td>
<td>996</td>
</tr>
<tr>
<td>BP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.22</td>
<td>$2.18</td>
<td>$2.18</td>
<td>$28.00</td>
<td>$59.0K</td>
<td>1.1K</td>
<td>282</td>
</tr>
</tbody>
</table>

<h3>About BP</h3>
BP is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2023, it produced 1.1 million barrels of liquids and 6.9 billion cubic feet of natural gas per day. At the end of 2023, reserves stood at 6.8 billion barrels of oil equivalent, 55% of which are liquids. The company operates refineries with a capacity of 1.6 million barrels of oil per day.
Following our analysis of the options activities associated with BP, we pivot to a closer look at the company's own performance.
<h3>Where Is BP Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 4,307,829, the BP's price is down by -1.53%, now at $29.27. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 71 days.</li>
</ul>
<h3>Expert Opinions on BP</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $33.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Equal-Weight rating on BP with a target price of $33. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for BP, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

BP Options Trading: A Deep Dive into Market Sentiment

Investors with a lot of money to spend have taken a bullish stance on McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MCD, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 14 uncommon options trades for McDonald's.
This isn't normal.
The overall sentiment of these big-money traders is split between 42% bullish and 42%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $248,892, and 10 are calls, for a total amount of $742,365.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $220.0 and $320.0 for McDonald's, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of McDonald's stands at 1563.0, with a total volume reaching 2,381.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in McDonald's, situated within the strike price corridor from $220.0 to $320.0, throughout the last 30 days.
<h3>McDonald's 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732556721_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.4</td>
<td>$3.2</td>
<td>$3.4</td>
<td>$305.00</td>
<td>$221.0K</td>
<td>2.2K</td>
<td align="right">811</td>
</tr>
<tr>
<td>MCD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.45</td>
<td>$5.3</td>
<td>$5.3</td>
<td>$290.00</td>
<td>$159.0K</td>
<td>1.5K</td>
<td align="right">359</td>
</tr>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$28.0</td>
<td>$27.55</td>
<td>$28.0</td>
<td>$280.00</td>
<td>$70.0K</td>
<td>1.1K</td>
<td align="right">25</td>
</tr>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$28.15</td>
<td>$27.5</td>
<td>$27.75</td>
<td>$280.00</td>
<td>$69.3K</td>
<td>1.1K</td>
<td align="right">125</td>
</tr>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$27.45</td>
<td>$27.35</td>
<td>$27.45</td>
<td>$280.00</td>
<td>$68.6K</td>
<td>1.1K</td>
<td align="right">150</td>
</tr>
</tbody>
</table>

<h3>About McDonald's</h3>
McDonald's is the largest restaurant owner-operator in the world, with 2023 system sales of $130 billion across nearly than 42,000 stores and 115 markets. McDonald's pioneered the franchise model, building its footprint through partnerships with independent restaurant franchisees and master franchise partners around the globe. The firm earns roughly 60% of its revenue from franchise royalty fees and lease payments, with most of the remainder coming from company-operated stores across its three core segments: the United States, internationally operated markets, and international developmental/licensed markets.
<h3>Present Market Standing of McDonald's</h3>
<ul>
<li>With a trading volume of 1,991,998, the price of MCD is up by 0.68%, reaching $292.25.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 70 days from now.</li>
</ul>
<h3>Expert Opinions on McDonald's</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $325.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from TD Cowen downgraded its action to Hold with a price target of $300. 
&#x2A; Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on McDonald's with a target price of $335. 
&#x2A; An analyst from Truist Securities persists with their Buy rating on McDonald's, maintaining a target price of $342. 
&#x2A; An analyst from B of A Securities has decided to maintain their Neutral rating on McDonald's, which currently sits at a price target of $324. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for McDonald's with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

This Is What Whales Are Betting On McDonald's

Over half of Americans — 56% — say they plan to host guests for Thanksgiving this year. With costs rising 19% from last year, consumers are<a href="https://www.benzinga.com/news/econ-s/24/11/41944635/inflation-on-track-but-fed-may-go-slowly-on-interest-rate-cuts-experts-say"> feeling the pinch. </a>
What To Know: The cost of hosting Thanksgiving dinner in 2024 is up 19% from last year with an average of $431 spent on food, drink and decor for the event, according to <a href="https://www.lendingtree.com/credit-cards/study/thanksgiving-cost-report/">a survey</a> from LendingTree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>). 
"Whenever you start spending more, there's always going to be more risk. That's especially true when you're spending almost 20% more than last year," said Matt Schulz, LendingTree chief credit analyst.&nbsp;
"Most people's budgets are tight, leaving little financial wiggle room from month to month, so a 20% increase can be a big deal," Schulz added.&nbsp;
Read More: <a href="https://www.benzinga.com/news/global/24/11/42101365/indian-billionaire-one-of-the-worlds-richest-men-indicted-for-alleged-250-million-bribery-scheme">Indian Billionaire, One Of The World&#8217;s Richest Men, Indicted For Alleged $250 Million Bribery Scheme</a>
Survey respondents said they expect to spend an average of $265 on food and drinks and $166 on decor for an average of 11 guests at their table for the holiday this year. Most hosts — 60% — expect their guests to pitch in with either money or an item to offset expenses with 25% saying they may reconsider sending an invitation next year to a guest that arrives empty-handed. 
More than a third — 36% — of potential hosts say the amount they will spend on Thanksgiving will be a financial strain with 34% of potential hosts planning to use credit cards for Thanksgiving costs. Strikingly, 14% of hosts already regret their decision to do so. 
Sales and Promos: According to the survey, 30% of potential hosts will shop around, while 22% will use coupons and 33% will do both to help to offset costs. Retailers are trying to ease the financial strain by offering special Thanksgiving promotions and sales events.&nbsp;
Walmart, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) is promoting its Inflation-Free Thanksgiving Meal for 2024, which the company says allows customers to prepare the holiday meal for under $7 per person. The total cost for the meal to serve eight people is just over $53 and includes turkey, stuffing, gravy, cranberry sauce and dessert. 
Albertsons Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) is offering a Thanksgiving promotion for a free 16- to 20-pound turkey when customers spend $150 or more on groceries in a single transaction. Target Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) has brought back its Thanksgiving meal deal, priced at $20, for four people. In addition to the meal, Target is offering frozen turkeys at 79 cents per pound, a 20% reduction from last year. 
"It's such old and cliched advice, but it's true," Schulz says. "Taking the time to comparison shop can save you significant money at the holidays or any other time of year."
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a></li>
</ul>
Photo: Shutterstock

Retail Sales

Personal Finance

TREE

Thanksgiving Dinner Gobbles Up 19% More Cash This Year, Many Holiday Hosts 'Already Regret Their Decision'

Schneider National, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) disclosed that it has agreed to acquire Cowan Systems, LLC and its affiliates for approximately $390 <a href="https://www.benzinga.com/pressreleases/24/11/b42167845/schneiders-dedicated-momentum-continues-to-build-with-latest-acquisition-of-cowan-systems-llc" target="_blank" rel="noreferrer noopener">million in cash, subject to adjustments</a>.
The deal also includes a separate purchase of related real estate assets for $31 million.
Cowan Systems is primarily a dedicated contract carrier with a portfolio of complementary services including brokerage, drayage and warehousing. The company operates approximately 1,800 trucks and 7,500 trailers across more than forty locations throughout the Eastern and Mid-Atlantic regions of the U.S.
Including Cowan Systems, Schneider will operate over 8,400 Dedicated tractors, approximately&nbsp;70%&nbsp;of Schneider&#8217;s Truckload fleet.
The acquisition is expected to be earnings accretive for Schneider within the first year, excluding anticipated synergies.
The transaction is expected to close in the fourth-quarter 2024, pending customary conditions, and will be financed through existing cash and a new $400 million delayed draw term credit facility.
Post-acquisition, Cowan Systems&#8217; financials will be integrated into Schneider&#8217;s Truckload and Logistics segments.
This deal follows previous acquisitions of Midwest Logistics Systems and M&amp;M Transport Services, reinforcing Schneider&#8217;s growth in Dedicated contract carriage.
&#8220;This acquisition aligns with Schneider&#8217;s long-term vision to have customer-centric Dedicated solutions as the cornerstone of its Truckload segment. By complementing our organic Dedicated growth success with transactions like this, we are broadening our presence to provide greater value to our customers and stakeholders,&#8221; said Schneider President and CEO Mark Rourke. 
As of September 30, 2024,&nbsp;the company had cash and<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41774105/schneider-national-inc-announces-third-quarter-2024-results" rel="noreferrer noopener"> cash equivalents of $179.0 million</a>.
Investors can gain exposure to the stock via Tidal ETF Trust Aztlan North America Nearshoring Stock Selection ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRSH#NYSE">NRSH</a>).
Price Action: SNDR shares are up 2.10% at $32.28&nbsp;at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41809045/these-analysts-revise-their-forecasts-on-schneider-national-following-q3-earnings" target="_blank" rel="noreferrer noopener">These Analysts Revise Their Forecasts On Schneider National Following Q3 Earnings</a></li>
</ul>
Photo via Shutterstock.

Mid Cap

Movers

NRSH

SNDR

Schneider Expands Its Fleet: $390 Million Cowan Systems Deal Supercharges Dedicated Services

JP Morgan analyst Adrian Heurta downgrades Summit Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) from Overweight to Neutral and raises the price target from $43 to $52.5.

JP Morgan Downgrades Summit Materials to Neutral, Raises Price Target to $52.5

Asset manager WisdomTree overseeing $113 billion in assets, has filed to establish a trust entity in Delaware as a preliminary step toward launching an XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41142958/ripple-etf-could-it-happen-bitwises-filing-faces-uncertain-path-amid-regulatory-concerns">exchange-traded fund (ETF).</a>
What Happened: If successful, the ETF would track the price of XRP, the sixth-largest cryptocurrency by market capitalization, and join a growing list of applications for crypto ETFs, which are reshaping institutional access to digital assets.
The filing follows similar moves by Bitwise and Canary Capital, who are also seeking approval for XRP ETFs. 
WisdomTree's proposed XRP ETF is part of a wave of filings from investment firms aiming to provide U.S. investors with easier access to cryptocurrency markets. 
Last week, Bitwise submitted an <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42139601/solana-hits-264-record-high-as-etf-filings-regulatory-optimism-drive-market-momentum">S-1 registration statement</a> for a Solana ETF, signaling a shift toward diversified crypto ETF products.
However, XRP&#8217;s journey to becoming an ETF-backed asset faces significant regulatory hurdles, given Ripple's ongoing legal battles with the U.S. Securities and Exchange Commission (SEC).
Ripple Labs, the issuer of XRP, has been embroiled in a legal dispute with the SEC, which accuses the company of selling XRP as an unregistered security. 
Although Ripple secured a partial victory in 2023, ruling that retail XRP sales did not violate securities laws, <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42131449/with-gary-gensler-preparing-to-quit-in-2025-secs-crypto-cases-likely-to-quietly-go-away-amid-trumps-pro-bitcoin-stance-says-pantera-capitals-katrina-paglia">the SEC</a> has appealed.
This regulatory uncertainty complicates the path to ETF approval for XRP.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42169183/dont-get-fooled-by-the-success-of-dogecoin-shiba-inu-76-of-x-twitter-influencers-promote-dead-meme-coins-study-reveals">Don&#8217;t Get Fooled By The Success Of Dogecoin, Shiba Inu: 76% Of X (Twitter) Influencers Promote Dead Meme Coins, Study Reveals</a>
Why It Matters: Brad Garlinghouse, Ripple&#8217;s CEO, remains optimistic about the inevitability of an XRP <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41520740/ripple-ceo-expects-xrp-etf-as-institutional-demand-for-crypto-grows">ETF despite these challenges.</a>
"Since funds holding Bitcoin were first approved in January, $17 billion has flowed into the fastest-growing ETF in history," Garlinghouse said, emphasizing the growing appetite for crypto ETFs among institutional investors.
WisdomTree's filing follows a growing trend highlighted by 21Shares' recent application for a spot XRP ETF, the 21Shares Core XRP Trust, to be <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41693909/xrp-etf-coming-soon-21shares-files-for-one-despite-ripples-legal-battles">listed on the Cboe BZX Exchange.</a> 
21Shares' filing comes amid the SEC's legal scrutiny of Ripple, with accusations that Ripple raised $1.3 billion through unregistered XRP sales. 
The demand for crypto ETFs comes as the market anticipates clearer regulations and <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42098407/donald-trump-reportedly-eyeing-the-first-crypto-focused-role-in-the-white-house">broader adoption of digital assets.</a>
Industry experts, like Nate Geraci, President of the ETF Store, described Bitwise&#8217;s move to file for an XRP ETF as "strategic," despite legal challenges. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42166673/drug-cartels-use-tether-and-bitcoin-to-launder-millions-court-documents-reveal">Drug Cartels Use Tether And Bitcoin To Launder Millions, Court Documents Reveal</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$XRP

WisdomTree Files For XRP ETF Trust: Report

Jefferies analyst John Colantuoni maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Buy and raises the price target from $120 to $175.

RDDT

Jefferies Maintains Buy on Reddit, Raises Price Target to $175

Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) faces challenges in Indonesia as the government deems the tech giant&#8217;s proposed $100 million investment insufficient to lift a ban on selling <a href="https://www.benzinga.com/topic/iphone">its latest iPhone model.</a> The restriction is tied to regulations mandating that smartphones sold domestically must contain at least 40% locally sourced components.
Indonesia&#8217;s Industry Minister, Agus Gumiwang Kartasasmita, stated that Apple&#8217;s proposal needs to align with fairness principles, particularly when compared to the company&#8217;s more significant investments in Vietnam and Thailand, the Bangkok Post <a href="https://www.bangkokpost.com/business/investment/2908486/indonesia-says-apples-100m-investment-proposal-inadequate" target="_blank" rel="noreferrer noopener">reports</a>.
Also Read: <a href="https://www.benzinga.com/24/11/42161830/sony-eyes-portable-gaming-market-with-new-handheld-console-in-development" target="_blank" rel="noreferrer noopener">Sony Eyes Portable Gaming Market With New Handheld Console In Development</a>
Google Pixel phones, manufactured by Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), are also barred from sales in Indonesia due to similar non-compliance with local component requirements.
Companies typically partner with local suppliers or source parts domestically to meet these rules. Apple, however, still needs manufacturing facilities in Indonesia. Since 2018, it has relied on application-developer academies to partially fulfill local content mandates for older iPhone models.
Minister Agus disclosed that Apple still has an outstanding $100 million investment commitment that was originally set to be fulfilled by 2023. The Indonesian government is pushing for additional investments to extend through 2026. The ministry plans to invite Apple representatives to Indonesia for negotiations to discuss the situation further.
Agus emphasized that Apple must align its investments with the country&#8217;s expectations, noting that similar efforts in neighboring countries make Indonesia&#8217;s demands reasonable.
The push to increase local content in electronics aligns with Indonesia&#8217;s broader strategy to bolster its domestic manufacturing ecosystem and attract equitable foreign investment.
Initially, Apple <a target="_blank" href="https://www.benzinga.com/24/11/42071334/apples-100-million-gamble-tech-giant-moves-to-lift-indonesias-iphone-ban" rel="noreferrer noopener">proposed a $10 million</a> investment to address the shortfall, but Indonesia&#8217;s Ministry of Industry rejected the offer, maintaining the sales ban.
Apple&#8217;s earlier $10 million plan targeted accessory and component manufacturing but failed to satisfy Indonesia&#8217;s regulatory standards.
While Apple has invested $95 million in Indonesia via developer academies, it still falls $5 million short of the 1.7 trillion rupiah ($109.6 million) target.
In October, Morgan Stanley analyst Erik Woodring rated Apple as Overweight with a $273 price target, citing steady <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41350919/apple-analyst-predicts-a-september-quarter-revenue-beat-allays-fears-over-shorter-i" target="_blank" rel="noreferrer noopener">iPhone 16 lead times</a>.
Woodring noted that iPhone 16 Pro/Pro Max lead times extended globally, reflecting better supply stability than previous cycles.
Apple&#8217;s proactive supply-chain measures helped avoid shortages, balancing iPhone Pro/Pro Max demand and supply earlier than before.
Morgan Stanley forecasts 225 million iPhone shipments in 2024, with a potential 3% revenue upside from more robust September-quarter sales.
Price Action: AAPL stock is up 0.14% at $230.19 at the last check on Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42166116/amd-boosts-india-investments-400-million-pledged-supercomputers-in-the-works" target="_blank" rel="noreferrer noopener">AMD Boosts India Presence With $400 Million Investment, Supercomputers For Weather Forecasting</a></li>
</ul>
Photo: Shutterstock

Asia

Government

Regulations

Tech

Media

AAPL

GOOG

GOOGL

Apple $100 Million Proposal Rejected As Indonesia Maintains iPhone Ban

Agilent Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) will release earnings results for the fourth quarter, after the <a href="https://www.benzinga.com/quote/A/news">closing bell on Monday, Nov. 25.</a>
Analysts expect Agilent to report quarterly earnings at $1.41 per share. That's up from $1.38 per share a year ago. The Santa Clara, California-based company projects to report quarterly revenue of $1.67 billion, compared to $1.69 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Nov. 20, Agilent raised its quarterly dividend to 24.8 cents per share of common stock, a 5% increase over the previous dividend.
Agilent shares gained 1.4% to close at $133.84 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TJX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/592d5dec290fa7000185334c/brandon-couillard">Wells Fargo analyst Brandon Couillard</a> initiated coverage on the stock with an Overweight rating and a price target of $157 on Aug. 27. This analyst has an accuracy rate of 73%.</li>
<li>UBS analyst Elizabeth Garcia maintained a Neutral rating and raised the price target from $141 to $150 on Aug. 22. This analyst has an accuracy rate of 68%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5bc7068a211e20000159fa0a/patrick-donnelly">Citigroup analyst Patrick Donnelly</a> maintained a Buy rating and lifted the price target from $150 to $165 on Aug. 22. This analyst has an accuracy rate of 64%.</li>
<li>TD Cowen analyst Dan Brennan maintained a Buy rating and boosted the price target from $153 to $160 on Aug. 22. This analyst has an accuracy rate of 65%.</li>
<li>B of A Securities analyst Derik De Bruin maintained a Neutral rating and raised the price target from $140 to $147 on Aug. 22. This analyst has an accuracy rate of 75%.</li>
</ul>
Considering buying Agilent stock? Here&#8217;s what analysts think:
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Earnings

Agilent Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Cocrystal Pharma (COCP – Research Report), with a price ...

Cocrystal Pharma (COCP) Receives a Buy from Noble Financial

Earnings Week Ahead: Walmart, Home Depot, Alibaba, Cisco and more

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cocrystal Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/cocp-stock-quote/">COCP</a>) just reported results for the second quarter of 2024.<ul><li>Cocrystal Pharma reported earnings per share of -53 cents. This was below the analyst estimate for EPS of -48 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/cocp-stock-earnings-cocrystal-pharma-for-q2-of-2024/">COCP Stock Earnings: Cocrystal Pharma Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

COCP Stock Earnings: Cocrystal Pharma Misses EPS for Q2 2024

Cocrystal Pharma GAAP EPS of -$0.53 misses by $0.03

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cocrystal Pharma (COCP – Research Report) and IGM Bi...

Analysts Offer Insights on Healthcare Companies: Cocrystal Pharma (COCP) and IGM Biosciences (IGMS)

Cocrystal Pharma (COCP) has issued an update. Cocrystal Pharma, Inc. has announced its plans to participate in upcoming investment conferences, sig...

Cocrystal Pharma Engages Investors at Upcoming Conferences

In a report released today, Ram Selvaraju from H.C. Wainwright maintained a Buy rating on Cocrystal Pharma (COCP – Research Report), with a price t...

Buy Rating Affirmed for Cocrystal Pharma Amid Promising Drug Pipeline and Strong Clinical Results

The latest announcement is out from Cocrystal Pharma ( ($COCP) ). Cocrystal Pharma, Inc. has rewarded its top executives and non-employee directors...

Cocrystal Pharma Boosts Executive and Director Compensation

Cocrystal Pharma ( ($COCP) ) has issued an announcement. Cocrystal Pharma, Inc. is leveraging its innovative, structure-based drug discovery platfo...

Cocrystal Pharma Advances Antiviral Drug Development

Cocrystal Pharma GAAP EPS of -$0.49 beats by $0.08

AMAT

ASXC

ATOS

BABA

BATL

BEEM

BEKE

BLDP

BLUE

CARA

CATX

COCP

CSCO

CTRM

ESPR

GLNG

GOEV

GOLD

GRAB

HUYA

IGMS

JAGX

KNDI

LITE

MDAI

MIRA

MMAT

MNDY

NNDM

OGEN

OUST

PSFE

RRAC

SACH

STNE

TAYD

TCEHY

TCRT

VUZI

WKHS

XXII

Press Releases

Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows

Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Events

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts

Cocrystal Pharma's Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins

Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Comments

Cocrystal Pharma

Cocrystal Pharma (COCP) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL